Last reviewed · How we verify
PROMETRIUM® 400 mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
PROMETRIUM® 400 mg (PROMETRIUM® 400 mg) — Solvay Pharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PROMETRIUM® 400 mg TARGET | PROMETRIUM® 400 mg | Solvay Pharmaceuticals | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PROMETRIUM® 400 mg CI watch — RSS
- PROMETRIUM® 400 mg CI watch — Atom
- PROMETRIUM® 400 mg CI watch — JSON
- PROMETRIUM® 400 mg alone — RSS
Cite this brief
Drug Landscape (2026). PROMETRIUM® 400 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/prometrium-400-mg. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab